Dive Brief:

潜水简介：

23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with the U.S. Securities and Exchange Commission.

根据周三提交给美国证券交易委员会的文件，23andMe首席执行官安妮·沃西基计划将这家DNA检测公司私有化。

Wojcicki currently owns more than 20% of the firm’s total outstanding shares, and about 49% of voting rights. She plans to acquire all outstanding shares of the company.

Wojcicki目前拥有该公司总流通股的20%以上，约49%的投票权。她计划收购公司的所有流通股。

The CEO wants to maintain control of 23andMe and would not be willing to support any alternative transaction, according to the filing.

根据备案文件，这位首席执行官希望维持对23andMe的控制，不愿意支持任何替代交易。

Dive Insight:

潜水洞察：

23andMe, which makes consumer genetic tests, has been looking at strategic alternatives as its shares have fallen. The firm went public in 2021 through a merger with a special purpose acquisition company valuing 23andMe at $3.5 billion. Its stock has traded below a dollar this year, down from its IPO price of $10 per share..

23andMe是一家进行消费者基因检测的公司，随着其份额的下降，它一直在寻找战略替代品。该公司于2021年通过与一家价值35亿美元的23andMe特殊目的收购公司的合并而上市。其股票今年的交易价格低于一美元，低于每股10美元的IPO价格。。

23andMe has also expanded into drug research by using its database built up through the DNA testing business, with Wojcicki claiming the company was a full-fledged biotech.

23andMe还利用其通过DNA检测业务建立的数据库扩展到药物研究领域，Wojcicki声称该公司是一家成熟的生物技术公司。

In February, Wojcicki discussed splitting up the consumer and therapeutics businesses as a potential option. 23andMe’s board formed a special committee last month, composed of independent directors, to review strategic alternatives.

2月，Wojcicki讨论了将消费者和治疗业务分开作为一种潜在的选择。23andMe董事会上个月成立了一个由独立董事组成的特别委员会，以审查战略替代方案。

Now, the CEO is considering taking the company private, a move that TD Cowen analysts said could be the “new most likely outcome” in a Thursday research note.

现在，首席执行官正在考虑将公司私有化，TD Cowen分析师在周四的研究报告中表示，此举可能是“最有可能的新结果”。

Wojcicki is working with advisers and plans to seek out potential partners and financing sources, according to the SEC filing. The special committee would review her proposal once it’s available, alongside other options, including continuing to operate as a publicly traded company.

根据SEC提交的文件，Wojcicki正在与顾问合作，并计划寻找潜在的合作伙伴和融资来源。一旦她的提议可用，特别委员会将与其他选择一起审查，包括继续作为上市公司运营。

The Cowen analysts wrote the company has been challenged because biotech investors, who would be interested in the therapeutics side of the business, don’t want to be involved in a direct-to consumer platform. Other investors might be interested in a mature healthcare business but don’t want to support the cash burn of therapeutics. .

考恩（Cowen）的分析师写道，该公司受到了挑战，因为生物技术投资者对该业务的治疗方面感兴趣，不想参与直接面向消费者的平台。其他投资者可能对成熟的医疗保健业务感兴趣，但不想支持治疗的现金消耗。。

“A potential business split, which has been previously discussed, remains on the table in our view and addresses the central dilemma of 23andMe shares, but beyond that options are seemingly limited, in our view,” they wrote. “We view the company turning private from Ms. Wojcicki's proposal as the new most likely outcome which should be welcomed by investors.” .

他们写道：“在我们看来，之前已经讨论过的潜在业务分割仍然存在，并解决了23andMe股票的核心困境，但在我们看来，除此之外，选择似乎是有限的。”。“我们认为这家公司从Wojcicki女士的提议转为私有是最有可能的新结果，应该受到投资者的欢迎。”。

23andMe has faced financial pressure as sales of DNA tests have declined and an exclusive research collaboration with GlaxoSmithKline ended last year. In its fiscal third quarter, ending Dec. 31, revenues fell about 33% year over year to $44.7 million.

23andMe面临着财务压力，因为DNA测试的销售额下降，并且去年与葛兰素史克（GlaxoSmithKline）的独家研究合作结束。在截至12月31日的第三财季，收入同比下降约33%，至4470万美元。

After a data breach last year affected 6.9 million people, the company now faces multiple lawsuits from its customers.

在去年一次数据泄露影响了690万人之后，该公司现在面临着来自其客户的多起诉讼。